Discover personalized clinical trial options designed to support your journey β safely, confidentially, and at no cost.
Takes less than 2 minutes β’ 100% confidential
Type 2 diabetes is a chronic metabolic disease in which the body either does not produce enough insuβ¦
Increased thirst, Frequent urination, Unexplained fatigue and more.
Obesity and excess visceral adiposity; Physical inactivity and sedentary lifestyle.
Metformin, GLP-1 Receptor Agonists and more.
Overview
Type 2 diabetes is a chronic metabolic disease in which the body either does not produce enough insulin or cannot effectively use the insulin it produces, leading to elevated blood glucose levels. It accounts for over 90% of all diabetes cases globally and is closely linked to obesity, physical inactivity, and genetic predisposition. With lifestyle changes and modern medications, many people can achieve near-normal blood sugar control or even remission.
Prevalence
422M adults globally
Worldwide statistics
Symptoms
Common Symptoms
Quality of Life Impact
Uncontrolled diabetes leads to serious complications including heart disease, kidney failure, blindness, and lower-limb amputation. With good glucose management, people with type 2 diabetes can live full, healthy lives.
With the right care and support, most people live full, active lives.
Causes & Risk Factors
Health Insights
Active Global Trials
67+
Across all phases
Symptom Frequency
78%
Patients report primary symptom
Trial Improvement Rate
68%
Report improvement within 3 months
Avg. Trial Duration
14 mo
Median length of participation
Symptom Frequency Among Patients
Treatment
Cornerstone first-line medication β reduces hepatic glucose production, low cost, well tolerated.
Semaglutide, liraglutide β weight loss, cardiovascular protection, injectable or oral.
Empagliflozin, dapagliflozin β kidney and heart protection, excretes glucose in urine.
Required when oral medications cannot maintain target glucose levels.
Mediterranean or low-carb diet + 150 min/week exercise β can achieve remission.
For BMI β₯ 35 β can produce complete diabetes remission in up to 80% of cases.
Clinical Trials
National Institute of Diabetes
Comparing a structured low-carbohydrate eating plan to standard dietary guidelines for blood sugar management.
NCT05634892
Daily Life
You are not alone. Millions of people navigate Type 2 Diabetes every day β and with the right support system and treatments, a meaningful life is absolutely within reach.
Community Support
Connect with thousands of patients and caregivers
Digital Tools
Track symptoms and share insights with your care team
Specialist Network
Access to leading neurologists and researchers
Education Hub
Evidence-based resources tailored to your journey
Check Your Eligibility
Our quick eligibility check matches you with trials that fit your profile β no commitment required.
Age 30+
Most T2D trials target adults over 30
Type 2 diabetes diagnosis
Confirmed HbA1c or glucose criteria
Current treatment status
On medication, diet-controlled, or newly diagnosed
Takes less than 2 minutes
No cost β’ No obligation β’ No spam
Why Join a Trial
Try innovative therapies before they're widely available β some with breakthrough potential.
Receive close monitoring and support from leading specialists throughout the trial.
Study-related care, tests, and the investigational treatment are provided at no charge.
Research Pipeline
Current pipeline overview for Type 2 Diabetes
Pipeline data is indicative. Source: ClinicalTrials.gov & WHO ICTRP.
Partners
Type 2 Diabetes Foundation
Patient advocacy & education
β PAG EndorsedRARE-UAE
Gulf region patient networks
β PAG EndorsedNews
Tirzepatide Shows 22% Weight Loss in Landmark SURMOUNT-5 Trial
Eli Lilly's tirzepatide demonstrated superior weight loss compared to semaglutide in the head-to-head SURMOUNT-5 trial, with a mean reduction of 22.8% body weight.
NIH Β· Mar 10, 2025
FDA Issues Safety Alert on Two Popular SGLT-2 Inhibitors Over Rare Kidney Risk
The FDA has updated safety labeling for empagliflozin and dapagliflozin following reports of acute kidney injury in patients with pre-existing renal impairment.
FDA Β· Mar 8, 2025
UAE Reports 40% Drop in Uncontrolled Diabetes Rates Following National AI Screening Program
The UAE's Ministry of Health reported a significant reduction in uncontrolled type 2 diabetes following the rollout of its AI-powered population-level screening program.
UAE Ministry of Health Β· Feb 20, 2025
FAQ
Resources
NIH MedlinePlus
Authoritative overview of Type 2 Diabetes from the National Institutes of Health.
Visit NIH β
π€Type 2 Diabetes Foundation
Patient advocacy resources, support groups, and disease education.
Visit Foundation β
π¨Emergency Guide
What to do in a Type 2 Diabetes-related emergency β share with family.
Download Guide β
βFAQ β Clinical Trials
Everything you need to know before enrolling in a clinical trial.
Read FAQ β
Your Journey Starts Here
Join thousands of patients who've found the right clinical trial through HEKMA β safely, confidentially, and at no cost.
Check Your EligibilityEli Lilly UAE
Head-to-head comparison of tirzepatide and insulin glargine in UAE adults with poorly controlled T2D.
NCT05401245
Dexcom
Assessing whether continuous glucose monitoring improves outcomes and reduces hypoglycemia in elderly T2D patients.
NCT05198765
